• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Lon­za ex­pands cap­sule foot­print; Bio­Cen­triq's new HQ

5 months ago
Manufacturing

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

5 months ago
Deals

Ex­clu­sive: Can oral an­ti­bod­ies work? A small start­up thinks it has an an­swer

5 months ago
R&D

2025 could bring some sun­shine for health tech star­tups

5 months ago
Financing
Health Tech

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

5 months ago
Special
Pharma

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

5 months ago
R&D

Ex­clu­sive: Col­or Health alums raise $10M for new start­up, us­ing AI for reg­u­la­to­ry work

5 months ago
Financing
AI

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

5 months ago
R&D

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

5 months ago
Deals
Cell/Gene Tx

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

5 months ago
Financing
Startups

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

5 months ago
Pharma
FDA+

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

5 months ago
Pharma
Law

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

5 months ago
Editor's note
China

Tessera gets up to $50M from the Gates Foun­da­tion; Tvar­di’s re­verse merg­er

5 months ago
News Briefing

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

5 months ago
Deals
China

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

5 months ago
People
Startups

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

5 months ago
Deals
Pharma

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

5 months ago
Deals

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

5 months ago
R&D
AI

Au­ri­on’s eye cell ther­a­py im­proves vi­sion in small study, plots Phase 3 tri­al

5 months ago
R&D

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

5 months ago
Financing
Startups

Jazz Phar­ma­ceu­ti­cals CEO and co-founder Bruce Cozadd is re­tir­ing

5 months ago
People
Pharma

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

5 months ago
Pharma
Law

San­doz inks $275M set­tle­ment in gener­ic an­titrust lit­i­ga­tion

5 months ago
Pharma
Law
First page Previous page 62636465666768 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times